Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 4/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.34 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8014420 | 0.74 | ESR1 (0.40) | ESR1ESR2PPARAPPARGTRPV1 | |
| SCHEMBL8015012 | 0.73 | PPARD (0.39) | ESR1ESR2PPARAPPARGTRPV1 | |
| SCHEMBL8037397 | 0.72 | PPARD (0.57) | PPARAPPARGPPARD | |
| SCHEMBL19806082 | 0.72 | TRPV1 (0.35) | ALDH1A1MAPK1PPARAPPARGTRPV1 | |
| SCHEMBL1855926 | 0.71 | TRPV1 (0.37) | MAPTALDH1A1HPGDTRPV1TRPV4 | |
| SCHEMBL1856329 | 0.71 | TRPV1 (0.37) | MAPTALDH1A1HPGDTRPV1TRPV4 | |
| SCHEMBL1866161 | 0.71 | TRPV1 (0.37) | MAPTALDH1A1HPGDTRPV1TRPV4 | |
| SCHEMBL5690949 | 0.71 | TRPV1 (0.37) | MAPTALDH1A1HPGDTRPV1TRPV4 | |
| SCHEMBL23119102 | 0.70 | TRPV1 (0.38) | ALDH1A1HPGDTRPV1TRPV4 | |
| SCHEMBL8008760 | 0.69 | PPARD (0.46) | PPARAPPARGTRPV1TRPV4PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2021-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | NLRP3, PYCARD, IAPP | HTR6 3122/4885NPC1 799/4885MAPT 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.